211 related articles for article (PubMed ID: 35039194)
1. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
[TBL] [Abstract][Full Text] [Related]
2. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
[TBL] [Abstract][Full Text] [Related]
3. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
Wilck M; Cornely OA; Cordonnier C; Velez JD; Ljungman P; Maertens J; Selleslag D; Mullane KM; Nabhan S; Chen Q; Dagan R; Richmond P; Daus C; Geddie K; Tamms G; Sterling T; Patel SM; Shekar T; Musey L; Buchwald UK;
Clin Infect Dis; 2023 Oct; 77(8):1102-1110. PubMed ID: 37338158
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
Platt HL; Greenberg D; Tapiero B; Clifford RA; Klein NP; Hurley DC; Shekar T; Li J; Hurtado K; Su SC; Nolan KM; Acosta CJ; McFetridge RD; Bickham K; Musey LK;
Pediatr Infect Dis J; 2020 Aug; 39(8):763-770. PubMed ID: 32639460
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).
Kishino H; Sawata M; Igarashi R; Shirakawa M; Pedley A; Musey L; Platt HL; Buchwald UK
Jpn J Infect Dis; 2022 Nov; 75(6):575-582. PubMed ID: 35908869
[TBL] [Abstract][Full Text] [Related]
8. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Martinon-Torres F; Wysocki J; Szenborn L; Carmona-Martinez A; Poder A; Dagan R; Richmond P; Gilbert C; Trudel MC; Flores S; Lupinacci R; McFetridge R; Wiedmann RT; Chen Q; Gerrits H; Banniettis N; Musey L; Bickham K; Kaminski J;
Vaccine; 2023 May; 41(21):3387-3398. PubMed ID: 37105892
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
Quinn CT; Wiedmann RT; Jarovsky D; Lopez-Medina E; Rodriguez HM; Papa M; Boggio G; Shou Q; Dagan R; Richmond P; Feemster K; McFetridge R; Tamms G; Lupinacci R; Musey L; Bickham K
Blood Adv; 2023 Feb; 7(3):414-421. PubMed ID: 36383730
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L;
AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).
Suzuki H; Fujita H; Iwai K; Kuroki H; Taniyama K; Shizuya T; Kishino H; Igarashi R; Shirakawa M; Sawata M
Vaccine; 2023 Jul; 41(34):4933-4940. PubMed ID: 37344262
[TBL] [Abstract][Full Text] [Related]
12. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
Bili A; Dobson S; Quinones J; Phongsamart W; Oberdorfer P; Kosalaraksa P; Dagan R; Richmond P; Wilck M; Vallejos W; Nunn C; McFetridge R; Tamms G; Fu R; Lupinacci R; Musey L; Banniettis N; Bickham K;
Vaccine; 2023 Jan; 41(3):657-665. PubMed ID: 36522265
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
Benfield T; Rämet M; Valentini P; Seppä I; Dagan R; Richmond P; Mercer S; Churchill C; Lupinacci R; McFetridge R; Park J; Wittke F; Banniettis N; Musey L; Bickham K; Kaminski J
Vaccine; 2023 Apr; 41(15):2456-2465. PubMed ID: 36841723
[TBL] [Abstract][Full Text] [Related]
14. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
Banniettis N; Wysocki J; Szenborn L; Phongsamart W; Pitisuttithum P; Rämet M; Richmond P; Shi Y; Dagan R; Good L; Papa M; Lupinacci R; McFetridge R; Tamms G; Churchill C; Musey L; Bickham K;
Vaccine; 2022 Oct; 40(44):6315-6325. PubMed ID: 36150974
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
Hammitt LL; Quinn D; Janczewska E; Pasquel FJ; Tytus R; Rajender Reddy K; Abarca K; Khaertynova IM; Dagan R; McCauley J; Cheon K; Pedley A; Sterling T; Tamms G; Musey L; Buchwald UK
Open Forum Infect Dis; 2022 Mar; 9(3):ofab605. PubMed ID: 35146039
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Severance R; Schwartz H; Dagan R; Connor L; Li J; Pedley A; Hartzel J; Sterling TM; Nolan KM; Tamms GM; Musey LK; Buchwald UK
Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 34726574
[No Abstract] [Full Text] [Related]
20. Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028).
Ishihara Y; Kuroki H; Hidaka H; Iwai K; Wan K; Shirakawa M; Sawata M
Hum Vaccin Immunother; 2023 Dec; 19(1):2180973. PubMed ID: 36882898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
